EA202092109A1 - КРИСТАЛЛИЧЕСКИЕ ФОРМЫ СТИМУЛЯТОРА sGC - Google Patents

КРИСТАЛЛИЧЕСКИЕ ФОРМЫ СТИМУЛЯТОРА sGC

Info

Publication number
EA202092109A1
EA202092109A1 EA202092109A EA202092109A EA202092109A1 EA 202092109 A1 EA202092109 A1 EA 202092109A1 EA 202092109 A EA202092109 A EA 202092109A EA 202092109 A EA202092109 A EA 202092109A EA 202092109 A1 EA202092109 A1 EA 202092109A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crystalline forms
sgc stimulator
present
sgc
fluorobenzyl
Prior art date
Application number
EA202092109A
Other languages
English (en)
Russian (ru)
Inventor
Кваме В. Нти-Аддае
Лина Кумари Прасад
Томас Сторц
Original Assignee
Сайклерион Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65818696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202092109(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сайклерион Терапьютикс, Инк. filed Critical Сайклерион Терапьютикс, Инк.
Publication of EA202092109A1 publication Critical patent/EA202092109A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA202092109A 2018-03-07 2019-03-07 КРИСТАЛЛИЧЕСКИЕ ФОРМЫ СТИМУЛЯТОРА sGC EA202092109A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862639846P 2018-03-07 2018-03-07
PCT/US2019/021080 WO2019173551A1 (en) 2018-03-07 2019-03-07 Crystalline forms of an sgc stimulator

Publications (1)

Publication Number Publication Date
EA202092109A1 true EA202092109A1 (ru) 2021-03-04

Family

ID=65818696

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092109A EA202092109A1 (ru) 2018-03-07 2019-03-07 КРИСТАЛЛИЧЕСКИЕ ФОРМЫ СТИМУЛЯТОРА sGC

Country Status (21)

Country Link
US (3) US11466015B2 (enExample)
EP (1) EP3762389B1 (enExample)
JP (1) JP7423539B2 (enExample)
KR (1) KR102782810B1 (enExample)
CN (1) CN111836812A (enExample)
AU (1) AU2019231724B2 (enExample)
BR (1) BR112020018212A2 (enExample)
CA (1) CA3092683A1 (enExample)
CL (5) CL2020002284A1 (enExample)
CO (1) CO2020012493A2 (enExample)
CR (1) CR20200458A (enExample)
EA (1) EA202092109A1 (enExample)
ES (1) ES2980256T3 (enExample)
IL (1) IL276853B2 (enExample)
MA (1) MA54638A (enExample)
MX (5) MX2020009183A (enExample)
PE (1) PE20210124A1 (enExample)
PH (1) PH12020551394A1 (enExample)
SG (1) SG11202008641WA (enExample)
TW (1) TWI823903B (enExample)
WO (1) WO2019173551A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111836812A (zh) 2018-03-07 2020-10-27 塞科里昂医疗股份有限公司 sGC刺激剂的晶型
US12220414B2 (en) * 2018-07-11 2025-02-11 Tisento Therapeutics Inc. Use of sGC stimulators for the treatment of mitochondrial disorders
US20230130739A1 (en) * 2020-03-26 2023-04-27 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS
CN118221651A (zh) * 2022-12-21 2024-06-21 广东东阳光药业股份有限公司 氟取代的吲唑化合物的晶型及其用途
AU2023412228A1 (en) * 2022-12-21 2025-07-03 Sunshine Lake Pharma Co., Ltd. Crystal form of fluorine-substituted indazole compound and use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
CZ302691B6 (cs) 1998-07-08 2011-09-07 Sanofi - Aventis Deutschland GmbH N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
CN101939053A (zh) 2007-09-06 2011-01-05 默沙东公司 可溶性的鸟苷酸环化酶活化剂
CA2711134A1 (en) 2008-01-24 2009-07-30 Merck Sharp & Dohme Corp. Angiotensin ii receptor antagonists
CA2743864A1 (en) 2008-11-25 2010-06-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CA2753434C (en) 2009-02-26 2014-07-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
UA107112C2 (uk) 2010-05-27 2014-11-25 Мерк Шарп Енд Доме Корп. Активатори розчинної гуанілатциклази
TWI532737B (zh) 2010-06-30 2016-05-11 艾諾屋製藥公司 可溶性鳥苷酸環化酶（ｓＧＣ）刺激物
WO2012058132A1 (en) 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
JP5878546B2 (ja) 2010-11-09 2016-03-08 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激剤
EP2927231B1 (en) 2012-11-30 2017-09-20 Astellas Pharma Inc. Imidazopyridine compounds
US9776997B2 (en) 2013-06-04 2017-10-03 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-A]pyridines and their use
CN104327107A (zh) * 2013-10-17 2015-02-04 广东东阳光药业有限公司 一种氟喹诺酮类抗菌药物的制备方法
US9796733B2 (en) 2014-06-04 2017-10-24 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
US10844064B2 (en) 2014-09-17 2020-11-24 Cyclerion Therapeutics, Inc. sGC stimulators
EP3227286B1 (de) * 2014-12-02 2018-12-26 Bayer Pharma Aktiengesellschaft Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung
IL264955B (en) 2016-09-02 2022-06-01 Ironwood Pharmaceuticals Inc Fused bicyclic sgc stimulators
CN111836812A (zh) 2018-03-07 2020-10-27 塞科里昂医疗股份有限公司 sGC刺激剂的晶型

Also Published As

Publication number Publication date
EP3762389B1 (en) 2024-02-28
IL276853B1 (en) 2026-01-01
MA54638A (fr) 2021-11-10
CL2021003536A1 (es) 2022-08-19
KR102782810B1 (ko) 2025-03-14
WO2019173551A8 (en) 2020-06-11
CR20200458A (es) 2020-11-09
CO2020012493A2 (es) 2020-10-30
IL276853B2 (en) 2026-05-01
US20250115611A1 (en) 2025-04-10
AU2019231724A1 (en) 2020-10-08
TWI823903B (zh) 2023-12-01
CL2021000301A1 (es) 2021-06-18
TW201940487A (zh) 2019-10-16
EP3762389A1 (en) 2021-01-13
MX2020009183A (es) 2020-10-08
MX2023004857A (es) 2023-11-24
ES2980256T3 (es) 2024-09-30
CN111836812A (zh) 2020-10-27
US12122782B2 (en) 2024-10-22
IL276853A (en) 2020-10-29
PH12020551394A1 (en) 2021-11-22
CA3092683A1 (en) 2019-09-12
CL2020002284A1 (es) 2020-11-27
WO2019173551A1 (en) 2019-09-12
JP7423539B2 (ja) 2024-01-29
KR20200128708A (ko) 2020-11-16
MX2023004856A (es) 2023-11-24
PE20210124A1 (es) 2021-01-19
US11466015B2 (en) 2022-10-11
MX2023004855A (es) 2023-11-24
CL2021003530A1 (es) 2022-08-19
US20230095799A1 (en) 2023-03-30
MX2023004858A (es) 2023-11-24
BR112020018212A2 (pt) 2020-12-29
JP2021515015A (ja) 2021-06-17
AU2019231724B2 (en) 2024-06-27
CL2021003531A1 (es) 2022-08-19
SG11202008641WA (en) 2020-10-29
US20210115050A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
PH12020551394A1 (en) CRYSTALLINE FORMS OF AN sGC STIMULATOR
EA202090659A1 (ru) СОСТАВЫ, СОДЕРЖАЩИЕ 6-(2-ГИДРОКСИ-2-МЕТИЛПРОПОКСИ)-4-(6-(6-((6-МЕТОКСИПИРИДИН-3-ИЛ)МЕТИЛ)-3,6-ДИАЗАБИЦИКЛО[3.1.1]ГЕПТАН-3-ИЛ)ПИРИДИН-3-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИДИН-3-КАРБОНИТРИЛ
MX2020008237A (es) Inhibidores de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol de cgas para tratar enfermedades autoinflamatorias.
EA201692095A1 (ru) Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака
NZ744349A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
EA201791727A1 (ru) 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-а]пиридо[3,4-е]пиримидин-5(1н)-он, его аналоги и соли и способы их применения в терапии
PE20120121A1 (es) Derivados de imidazopirazina como inhibidores de syk
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
EA202190323A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk
EA200800992A1 (ru) 2-амино-7,8-дигидро-6н-пиридо[4,3-d]пиримидин-5-оны, способ их получения, способ терапии с их помощью, компонент композиции и композиция на их основе, 2,4-диоксопиперидиновые соединения для их получения
PH12021552533A1 (en) Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease
PH12019502086A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
MX2021012129A (es) Composiciones y método para utilizarlas para el tratamiento de enfermedades neurodegenerativas y mitocondriales.
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
EA200870591A1 (ru) 2-фенил-5-амино-1,3,4-оксадиазолы и их применение в качестве лигандов никотинового рецептора ацетилхолина
JOP20170125A1 (ar) مركبات [8- (فنيل سلفونيل)-3، 8-ديازا ثنائي سيكلو [3. 2. 1] أوكتـ-3-يل] (1h-1، 2، 3-تريازول-4-يل) ميثانون
EA202190322A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ TRK
EA200800223A1 (ru) ПРОИЗВОДНЫЕ ПИРИДО[2,3-d]ПИРИМИДИНА, ИХ ПОЛУЧЕНИЕ, ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
MXPA05012082A (es) Compuestos como antagonistas del receptor crf1.
EA202092108A1 (ru) Способ получения стимуляторов растворимой гуанилатциклазы
CR20240134A (es) Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades autoinmunitarias
EA200600416A1 (ru) Производные циклопропила в качестве антагонистов рецептора nk3
SE0303451D0 (sv) New compounds
SE0100297D0 (sv) New compounds